RNAZ (TransCode Therapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate RNAZ?

The average price target is $0.00.

RNAZ Key Metrics

Key financial metrics for RNAZ
MetricValue
Price$6.35
Market Cap$5.66M
P/E Ratio-0.12
EPS$-52.59
Dividend Yield0.00%
52-Week High$739.20
52-Week Low$5.56
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$-34.66M
Gross Margin0.00%

RNAZ Analyst Consensus

RNAZ analyst coverage data. Average price target: $0.00.

Latest RNAZ News

Recent RNAZ Insider Trades

  • Fitzgerald Thomas A bought 49.35K (~$25.17K) on Sep 28, 2023.
  • Dudley Robert Michael bought 98.00K (~$49.98K) on Sep 28, 2023.
  • Dudley Robert Michael bought 12.00K (~$31.82K) on Jun 21, 2023.

Common questions about RNAZ

What do analysts rate RNAZ?
The average price target is $0.00.
Does Rallies show RNAZ price targets?
Yes. Rallies tracks RNAZ analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is RNAZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.
RNAZ

RNAZ